英文摘要 |
As electronic health (eHealth) has played a key role on the WHO agenda, 83% of WHO member states have implemented mobile health (mHealth) policies. The latest survey shows that the total number of mobile health applications (mHealth apps) on main mobile platforms has reached 260,000 and its market value is estimated to reach 31 billion USD by 2020. Since the majority of mHealth app publishers are technology companies or app developers rather than traditional healthcare industries, however, uncertainty about whether mHealth apps should be regulated as medical devices and governed by other laws and regulations might hinder their growth and development. The aim of this paper was to investigate the latest Federal Trade Commission (FTC) cases regarding the use of mHealth apps to detect melanoma and measure blood pressure. It also examined the Federal Drug Administration's (FDA) guidance and the FTC's interactive web tool to determine the regulatory approaches taken in the United States. In Taiwan, the TFDA issued medical software guidelines in 2015 and the highly controversial Article 6 of the Personal Information Protection Act regarding health information came into effect in March, 2016. To encourage the development of mHealth apps in Taiwan, we suggest the following: set up rules for end-users with different backgrounds and solve cross-border problems; help developers decide easily if regulations for medical devices apply, as well as how they comply with other laws and regulations; strike the perfect balance between innovation and health. |